SURVANTA® (beractant) Intratracheal Suspension is a sterile, non-pyrogenic pulmonary surfactant intended for intratracheal use only. It is a natural bovine lung extract containing phospholipids, neutral lipids, fatty acids, and surfactant-associated proteins to which colfosceril palmitate (dipalmitoylphosphatidylcholine), palmitic acid, and tripalmitin are added to standardize the composition and to mimic surface-tension lowering properties of natural lung surfactant. The resulting composition provides 25 mg/mL phospholipids (including 11.0-15.5 mg/mL disaturated phosphatidylcholine), 0.5-1.75 mg/mL triglycerides, 1.4-3.5 mg/mL free fatty acids, and less than 1.0 mg/mL protein. It is suspended in 0.9% sodium chloride solution, and heat-sterilized. SURVANTA contains no preservatives.
SURVANTA is indicated for prevention and treatment ("rescue") of Respiratory Distress Syndrome (RDS) (hyaline membrane disease) in premature infants. SURVANTA significantly reduces the incidence of RDS, mortality due to RDS and air leak complications.
In premature infants less than 1250 g birth weight or with evidence of surfactant deficiency, give SURVANTA as soon as possible, preferably within 15 minutes of birth.
To treat infants with RDS confirmed by x-ray and requiring mechanical ventilation, give SURVANTA as soon as possible, preferably by 8 hours of age.
Media Articles Related to Survanta (Beractant)
ARDS (Acute Respiratory Distress Syndrome)
Source: MedicineNet ICU Psychosis Specialty [2010.02.01]
Title: ARDS (Acute Respiratory Distress Syndrome)
Category: Diseases and Conditions
Created: 3/12/2007 12:00:00 AM
Last Editorial Review: 2/1/2010 12:00:00 AM
Published Studies Related to Survanta (Beractant)
A Randomized, Controlled Trial of Poractant Alfa versus Beractant in the Treatment of Preterm Infants with Respiratory Distress Syndrome. [2011.11.21]
We prospectively evaluated the differences in clinical responses and short-term outcomes in preterm infants with respiratory distress syndrome (RDS) treated with poractant alfa or beractant. Premature infants with RDS were randomized to poractant alfa or beractant treatment between July 2008 and June 2009...
Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome. [2010.10]
OBJECTIVE: Comparison of the differences between availability of animal-derived surfactant preparations used to treat premature infants is incomplete. The objective of this study was to assess the short-term treatment efficacy of the two most commonly used surfactant preparations in the United States, beractant (100 mg kg(-1) initial and subsequent doses) and poractant alfa (200 mg kg(-1) initial and 100 mg kg(-1) subsequent doses), in very premature, mechanically ventilated infants <30 weeks gestation with respiratory distress syndrome (RDS)... CONCLUSION: This study suggests significant short-term benefits to the use of the larger initial dose of poractant alfa than beractant in very premature infants with RDS. Further studies involving a larger number of preterm infants are needed to assess long-term effects.
Comparison of Infasurf (calfactant) and Survanta (beractant) in the prevention and treatment of respiratory distress syndrome. [2005.08]
BACKGROUND: In biophysical and animal testing, Infasurf develops lower surface tension and restores total surfactant activity better than Survanta... CONCLUSION: Early trial closure prevents us from either accepting or rejecting our null hypothesis.
A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. [2005.06]
AIM: To compare the effects of beractant and poractant in neonatal respiratory distress syndrome (RDS)... CONCLUSIONS: Infants with RDS treated with poractant had a lower FiO2 requirement during the first 48 h compared to infants who received beractant. Infants who received poractant also had fewer PDAs than infants who received beractant. The difference in FiO2 was not associated with a difference in age of first extubation, total intubation time, or incidence of bronchopulmonary dysplasia between groups.
A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. [2005.04]
BACKGROUND AND OBJECTIVE: Evidence suggests that synthetic surfactants consisting solely of phospholipids can be improved through the addition of peptides, such as sinapultide, that mimic the action of human surfactant protein-B (SP-B). A synthetic surfactant containing a mimic of SP-B may also reduce the potential risks associated with the use of animal-derived products. Our objective was to compare the efficacy and safety of a novel synthetic surfactant containing a functional SP-B mimic (lucinactant; Discovery Laboratories, Doylestown, PA) with those of a non-protein-containing synthetic surfactant (colfosceril palmitate; GlaxoSmithKline, Brentford, United Kingdom) and a bovine-derived surfactant (beractant; Abbott Laboratories, Abbott Park, IL) in the prevention of neonatal respiratory distress syndrome (RDS) and RDS-related death... CONCLUSIONS: Lucinactant is a more effective surfactant preparation than colfosceril palmitate for the prevention of RDS. In addition, lucinactant reduces the incidence of BPD, compared with colfosceril palmitate, and decreases RDS-related mortality rates, compared with beractant. Therefore, we conclude that lucinactant, the first of a new class of surfactants containing a functional protein analog of SP-B, is an effective therapeutic option for preterm infants at risk for RDS.
Clinical Trials Related to Survanta (Beractant)
Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants [Recruiting]
Approval of surfactant by the FDA in 1989 for the treatment of Respiratory Distress Syndrome
(RDS) in premature infants greatly improved survival rates. Newer surfactants approved by
the FDA were more concentrated and had a more rapid onset of action. The overall efficacy of
newer surfactants appeared similar until in 2004, Ramanathan and colleagues suggested that a
double dose of Curosurf improved survival in infants 25-32 weeks gestational age, compared
to infants treated with Survanta, the most commonly used surfactant preparation in the
United States. While the data was suggestive, it was not clear that the improvement in
survival was reproducible or that Curosurf was responsible for the improved survival rates.
The purpose of this study was to investigate the role of Curosurf in improving lung function
and survival rates and reducing the complications of prematurity in very premature infants <
30 weeks gestational age at birth.
Comparison in Pulmonary Compliance Between Curosurf and Survanta in Preterm Infants With Respiratory Distress Syndrome [Not yet recruiting]
This is a null hypothesis study. The investigators hypothesize that there will be no
difference in changes in dynamic compliance when measured at 15, 30, 45 and 60 minute
intervals after administration of either surfactant and there will be no differences in the
number of doses needed between the two surfactants in premature infants admitted to our
Early Surfactant to Reduce Use of Mechanical Breathing in Low Birth Weight Infants [Active, not recruiting]
Moderately premature infants with mild respiratory distress do not routinely receive
artificial surfactant early in their course of treatment. To test whether they might benefit
from early surfactant, infants who weigh 1250 to 2000 grams and have respiratory distress
syndrome will be randomized to either receive surfactant as soon as possible after
randomization, followed by extubation within 30 minutes and continuous positive airway
pressure (CPAP) or surfactant according to the usual practice of the center. This trial will
evaluate whether in infants with mild to moderate respiratory distress syndrome, early
administration of surfactant followed by extubation within 30 minutes and the use of CPAP
reduces the need for subsequent mechanical ventilation.
Prevention of Chronic Lung Disease (CLD) in Preterm Infants [Recruiting]
Pulmonary inflammation plays an important role in the early development of CLD. Postnatal
glucocorticoids have been shown effective in the prevention or treatment of CLD with various
success. However, systemic glucocorticoid therapy often associated with various short term
and long term complications. Therefore, modification of the therapeutic regimen is needed.
Inhaled steroid, including inhaled budesonide,have been tried but the results are
essentially unsuccessful, most likely due to small airways that the inhaled steroid reaching
to the peripheral lungs are limited and unpredictable. Direct instillation of budesonide
into the airway has also shown to be ineffective, possibly due to poor distribution of
steroid in the lungs.
The investigators hypothesize that intratracheal instillation of budesonide, a strong
tropical steroid, using surfactant as vehicle would facilitate the delivery of budesonide to
the lung periphery and would inhibit lung inflammation and improve the pulmonary outcome.
The result of our pilot study (Pediatrics, 2008) indicated this high possibility.
The Effect of Surfactant Administration on Cerebral Oxygenation [Recruiting]
The purpose of this study is to assess changes in cerebral oxygenation during two different
types (beractant and poractant) and two different routes (double lumen or single lumen
endotracheal tube) of surfactant administration using near infrared spectroscopy (NIRS).
Reports of Suspected Survanta (Beractant) Side Effects
Pulmonary Haemorrhage (5),
Drug Ineffective (1),
Medication Error (1),
Oxygen Saturation Decreased (1),
Neonatal Respiratory Distress Syndrome (1)
Page last updated: 2011-12-09